Petrovax

Russia
Naberezhnaya, Permskiy Kray, Russia, 123112

Company profile

Petrovax company profile

Petrovax is a leading Russian company engaged in research, development and production of innovative pharmaceuticals. The company owns a portfolio of original products, including vaccines, immune system medicines and prolonged biotech drugs. The company operates a modern GMP-compliant facility in the Moscow Region with annual capacity in liquid forms well above 150mn doses. Petrovax was one of the first Russian companies to receive a European GMP certificate and remains one of the few exporters of locally developed and produced drugs into the EU and the Middle East. Today Petrovax is the largest vaccines exporter in Russia. In 2020 Petrovax deeply engaged in COVID-19 Vaccine and Medication research and development, becoming the first Russian company to receive phase 3 clinical trial approvals for both.

Business identity

Operating status
Active
Company type
For Profit
Employee range
501-1,000 employees
Founded
1996-01-01, Year

Headquarters

Postal code
123112
Country code
RU
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Last funding
Series Unknown / 2014-02-01
Last equity funding
Series Unknown
Investors
1

Categories and groups

Founders and investors

Investors

Winter Capital